Intero Biosystems wants drugmakers to test on mini human intestines, not animals

Intero Biosystems is positioning itself at the forefront of the biotech industry by offering lab-grown human intestines to pharmaceutical companies. As global regulators increasingly push for alternatives to traditional animal testing, the startup’s organoid technology provides a more accurate and ethical method for drug development. By utilizing mini human intestines, researchers can better simulate human biological responses, potentially accelerating the drug discovery process and reducing the reliance on animal models. Intero Biosystems is currently focused on scaling its production capabilities and expanding the reach of its proprietary organoid technology. This shift represents a significant move toward more human-centric medical research, aligning with modern regulatory trends that prioritize precision and animal welfare in the pharmaceutical sector.